Sponsored By

Catalent Injecting $175M into Oral Dose Plant Expansion

The project at the Winchester, KY site will add 107,000 sq ft of space and expand its highly potent material handling capabilities.

2 Min Read
catalent_facility_image.jpeg
A sign outside of the headquarters of Catalent Inc., in Somerset, NJ. Representative image.Image courtesy of Kristoffer Tripplaar / Alamy Stock Photo

Pharmaceuticals, biologics, and consumer health firm Catalent announced plans Thursday for a $175 million expansion project at its large-scale oral dose forms facility in Winchester, KY that will add 107,000 sq ft of space and new capabilities.

Two new buildings will be constructed at the existing location, and the company will expand its highly potent material handling capabilities and containment vault. The project also includes the addition of capacity for the site’s existing turnkey operations, including dual fill encapsulation and pan coating, as well as packaging solutions and analytical services.

“We are witnessing a broad increase in demand for manufacturing, and the nature of the development pipeline being strong in both oncology treatments and complex molecules, necessitates the expansion of specific capabilities in areas such as highly potent materials handling,” said Aris Gennadios, Ph.D., president, Softgel & Oral Technologies for Catalent, in a company release. “Our Winchester site has a rich history in the successful commercialization of new products, and this expansion is the latest in a series of strategic investments, totaling hundreds of millions of dollars, to ensure that the current and future needs of our customers can be met.”

Work on the expansion is slated to reach completion by January 2024. Up to 277 new jobs will be created through the investment.

Catalent previously invested $40 million in 2015 to double the Winchester site’s footprint. The location opened in 1992.

Powder & Bulk Solids reported last month that Catalent is investing $350 million to expand the biologics drug substance and drug product manufacturing capabilities of its Bloomington, IN plant. New 2,000 L single-use bioreactors will be installed during the project and the firm plans to add downstream processing capabilities for drug substance, increasing the versatility of the location. The project also includes new quality control labs and additional packaging space with high-speed cartoning and auto-injector device assembly capabilities.

About the Author(s)

Powder Bulk Solids Staff

Established in 1983, Powder & Bulk Solids (PBS) serves industries that process, handle, and package dry particulate matter, including the food, chemical, and pharmaceutical markets.

Sign up for the Powder & Bulk Solids Weekly newsletter.

You May Also Like